Cytosorbents Seeks Shareholder Approval for Reverse Stock Split to Avoid Nasdaq Delisting

summarizeSummary

Cytosorbents is asking shareholders to approve a reverse stock split to boost its share price and avoid delisting from Nasdaq, a crucial step for the financially distressed company.

check_boxKey Events

• Reverse Stock Split Proposed

  Shareholders will vote on a reverse stock split at a ratio between 1-for-5 and 1-for-20 to increase the per-share price of common stock.

• Addresses Nasdaq Delisting Threat

  The primary purpose of the reverse split is to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting, following a 180-day extension granted until September 28, 2026.

• Annual Meeting Scheduled

  The virtual Annual Meeting of Stockholders is set for August 13, 2026, where the reverse stock split proposal and other routine matters will be voted upon.

• Critical for Capital Access Amid Distress

  This action is vital for the company's ability to raise future capital, especially in light of ongoing financial challenges, including a going concern warning and liquidity issues disclosed in recent filings.

auto_awesomeAnalysis

Cytosorbents is proposing a reverse stock split (1-for-5 to 1-for-20) to address its non-compliance with Nasdaq's minimum bid price rule. This is a critical measure to prevent delisting, which would severely impact the company's ability to raise capital. Given the company's recent going concern warnings, widened net losses, and deferred executive bonuses due to insufficient liquidity, maintaining its Nasdaq listing is paramount for its survival and future financing efforts. Shareholder approval is required at the upcoming annual meeting.